Written Question · S7W-01823 · Session 7
What assessment it has made of the impact on patient outcomes of the reported two-year gap in routine access to Oncotype DX testing for nod…
The question
To ask the Scottish Government what assessment it has made of the impact on patient outcomes of the reported two-year gap in routine access to Oncotype DX testing for node-positive breast cancer patients in Scotland compared with England and Wales, where NICE guidance was implemented in May 2024.
The answer
Recommendations regarding the use of tumour profiling tests such as Oncotype DX are developed independently of the Scottish Government. The Scottish Health Technologies Group (SHTG) published their recommendation in October 2023, which has been implemented in full. SHTG have criteria and processes in place to judge whether new evidence is sufficient to revise its existing recommendations.
In the Official Report
No contribution in the Official Report cites S7W-01823 by reference.